Eli Lilly's Mounjaro: the facts behind the medicine making headlines

The misconception worth clearing up first: Mounjaro is not just a stronger Ozempic

A belief that circulates widely online is that Mounjaro is essentially a higher-powered version of semaglutide, the same mechanism, just turned up. It is not. Semaglutide (sold as Wegovy for weight loss) activates one receptor: GLP-1. Eli Lilly's tirzepatide activates two: GLP-1 and GIP. The GIP pathway is not a small add-on. GIP receptors are expressed differently in the brain and in fat tissue compared with GLP-1 receptors, and the combined signal appears to produce a hunger-suppressing and metabolic effect greater than either pathway alone. That is not a marketing claim; it is the basis on which NICE evaluated the trial data and concluded tirzepatide produced greater average weight reduction than semaglutide 2.4 mg in a direct head-to-head trial, SURMOUNT-5, published in the New England Journal of Medicine in 2025.

Letting go of the "stronger Ozempic" framing matters because it changes how you think about side effects, dosing logic and why eligibility thresholds are structured as they are. These are genuinely different medicines. The full tirzepatide overview goes deeper on the receptor science if you want it.

What Eli Lilly's UK licence for tirzepatide actually permits

Eli Lilly's Mounjaro holds two UK licences. The first covers weight management: adults with a BMI of 30 or above, or 27 or above when at least one weight-related condition is present (such as hypertension, high cholesterol, type 2 diabetes, prediabetes or obstructive sleep apnoea). The second covers type 2 diabetes management. Lower BMI thresholds apply for certain ethnic backgrounds under UK guidance, a point the Mounjaro overview page covers in detail alongside the NICE eligibility criteria.

NICE recommended tirzepatide for NHS use in December 2024 (Technology Appraisal TA1026, updated September 2025) for adults with a BMI of 35 or above plus at least one weight-related comorbidity, with a phased NHS rollout now under way. Private treatment through a regulated pharmacy operates under the broader licensed eligibility: BMI 30 or above, or 27 or above with a qualifying condition, though a prescriber's full assessment still decides suitability in every individual case. The Eli Lilly Mounjaro product page covers the KwikPen format and storage in more detail. Both the NHS and private routes are documented in NICE's published recommendations.

The trial record: what SURMOUNT actually showed

Eli Lilly's tirzepatide clinical programme is called SURMOUNT, and the primary weight-management trial, SURMOUNT-1, randomised 2,539 adults with obesity (without diabetes) across sites worldwide. At 72 weeks, the highest dose produced an average body-weight reduction of around 20–21%. That figure comes from a peer-reviewed paper in the New England Journal of Medicine and was scrutinised in full by NICE before TA1026 was issued. It is worth saying clearly: those results apply to a clinical-trial population following structured lifestyle support alongside the medicine. Real-world outcomes vary.

Eli Lilly's tirzepatide sales grew sharply through 2024 as both the diabetes and weight-loss markets expanded, for context on the commercial scale of the programme, the 2024 sales overview sets out what is publicly reported. There has also been legal activity around compounded and counterfeit versions; the Eli Lilly tirzepatide lawsuit page explains what that means for UK patients considering treatment. The short version: only medicines sourced through the licensed UK supply chain carry the quality assurances the trials were built around. The NHS tirzepatide medicines page is a reliable plain-English reference for what to expect.

Side effects, the Black Triangle, and what the MHRA monitors

The most commonly reported side effects of Mounjaro are gastrointestinal: nausea, loose stools, constipation, indigestion and burping are all listed. They tend to be most noticeable after the first injection or a dose step, and often settle within a week or two as the body adjusts. Starting at 2.5 mg (a dose whose job is to let your system adapt, not to produce weight loss) is specifically designed to reduce that early discomfort.

The Black Triangle (▼) status means the MHRA requires healthcare professionals and patients to report any suspected side effects through the Yellow Card scheme. It does not mean the medicine is considered unsafe; it reflects that, as a relatively recently licensed product, regulators want a richer post-market safety picture. Pancreatitis is a known but infrequent risk across GLP-1 medicines: severe stomach pain that spreads to the back warrants urgent medical attention. Our page on hair thinning with Mounjaro covers one of the more frequently asked-about less-common effects. If cost context is relevant to your decision, the Mounjaro cost page sets out what private treatment typically involves and what a complete service should include.

Mounjaro is not licensed for anyone under 18, and is not recommended during pregnancy, while breastfeeding, or in the period before trying to conceive. Speak to our prescribers if you have questions about any of this before starting treatment.